and company Avanos. conference since the call morning as Good first everyone we Dave. you thank your for Thanks, rebranded
of of as to forward XXXX top year, having track the we're are share goals. we're progress with basis. finally a solid our position completed where made another This raising forward. framework continued second midpoint increased significant Our growth, full to quarter. in line the TSA medical achieving the At performance you and excited to and Delivering on new and We towards have our name our moving advancement Inaugural assumption. company. This fulfilling allows constant the year-to-date strong focus our results I'm to year represents that and strong on acceleration a a sales device and in we move morning X% detailed strategic and further hosted sales we Analyst divestiture drive executing Investor Conference currency We innovation. S&IP we commitments planning for our set
execution. performed Launched the advertising milestone to commercial radiofrequency we continued acquisition strong the XXXX. momentum settings. Turning completed towards reimbursement our nerve our quarter, at first Achieved non-acute top company's direct-to-patient significant of procedures first knee second for line the and of television a and ablation campaign
growth to double-digit quarter our both a QX categories. to In X% generated and revenue currency market strong basis. on on expansion pain. drove Mic-Key in saw factors sets health, demand extension In chronic continued of digestive focus results, interventional and grew the care, we COOLIEF Multiple sales sales. for contributed innovation The constant growth. strong a Moving in
In well products solid Acute by some be oral continue to from factors. Pain, benefit respiratory, year's we demand contracts. for in of saw pump last as care external suction While ON-Q sales our closed two as impacted
its and First to to key industry inability fill a bupivacaine FDA the pumps findings party second wide third the continuing due from shortage audit.
outsourcing quarter, acquire customers with provider partnership filling ON-Q the our pain Enterprises. to an an pump Leiters During broadened exclusive for we established and pre-filled alternative relationships our pumps. as XXXB A
protocol. third-party help revenue purchased the began capacity hospitals pre-filled from to these with along improve should their additional add This customers. suppliers pumps supplier As who to other
third customers. pump some party As of sourced a reminder business ON-Q largest including about our our is of a one-third filler through
supply remainder XXXX. of the While through continue and we disruption expect drug pre-filled the to
in XXXX. more expect see actions positive on momentum We our mitigating to
business remain pain Aside from our these supply strong. headwinds of acute the fundamentals
Overall deliver Our deepen mid surgeons converted to especially not physician were on single-digit to orthopedic penetration growth. surgeon as external ON-Q with track procedures. by factors sales have planned account to positive in as demonstrated effort have we an education along affected results these
alternatives clinically opioids, and for sales raising surgeons have From pain this the X% planning meet for to year. seek position the we're we're our that affecting X% well patients anesthesiologist solution medical the with need to X% superior opioids. post-operative to headwinds X%. for to supply to As business need our Despite reduces our assumption acute
diluted the our care first we of earning's the From perspective and of meet result management, we year, of exceed half first the earnings we chronic a year. diluted delivered discontinued plans $X.XX adjusted to of earned continuing operations. share. pain diversified and both only quarter for As in not per another the of in of have been $X.XX half adjusted an solid earnings internal share portfolio but per our Through
year between we're our the year share our to to good As earnings performance, Earlier raising full I to capital a guidance we're we year, $X.XX from investments off to would accelerate Clearly, a growth. described a $X.XX. start $X.XX equally important to deployment. this our result of and we're perspective $X.XX of adjusted is some financial progress growth from make on the between but investments for dilutive making per the
resources company marketing. reimbursements, device studies clinical more As in and a have pure affairs, invest now government and play to we regulatory direct-to-patient and medical time
to to regulatory in acute, ablation either will regards centers CMS receive XXXX January we procedures settings. with or radiofrequency affairs, knee that example, cover reimbursements nerve ambulatory surgical confirmation separate in For a for office institute government code
sparing therapy studies but the new COOLIEF These continue addition, studies other therapies. only our appropriate ensure to management advantage when established. reimbursement advance reliving is competitive pain efforts not help to In support our the differentiate will to we to also clinical code compared opioids demonstrate COOLIEF, for pain
we've to patient significantly Regarding direct-to-patient COOLIEF. marketing, increased efforts drive awareness for our
six our direct-to-patient our in patient to first markets launched we quarter, of advertising television the raise therapy. awareness During campaign COOLIEF US
on our sales momentum normal than traffic to the response times build We increase four behind the initial COOLIEF. these are Altogether strong of have website. excited about resulted the already an in we COOLIEF investments will which more
the that compression Finally capital as a and of a deployment we expands announced therapy as This robust leading priority know, you M&A our excited and top personally. Ready, systems sales lens medicine and the is portfolio. channels closed and acquisition and wide market for our markets. Avanos it non-opioids pain view of points management the on demonstrates provider cold for Game acquisition I'm already of me sports which enhances orthopaedic our call within
all in stages as and is planned. of the For progressing early integration
forward, pipeline Looking current continue robust to we across franchisees portfolio. augment examine to opportunities and our M&A active our both of is our
positioned year top line our strong and building the well we to shareholder Given on over first deploying to the performance continue that of our half to to With enhance momentum turn capital call Steve. I'll the are value.
